Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000301
Chunk: 104

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 104
---
 If it shall be found that any interest or other amount
deemed interest due hereunder shall violate applicable laws governing usury, the applicable rate of interest due hereunder shall automatically
be lowered to equal the maximum permitted rate of interest. The Company covenants (to the extent that it may lawfully do so) that it shall
not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury
law or other law which would prohibit or forgive the Company from paying all or any portion of the Principal of or Interest on this Note
as contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance
of this Note, and the Company (to the extent it may lawfully do so) hereby expressly waives all benefits or advantage of any such law,
and covenants that it will not, by resort to any such law, hinder, delay or impeded the execution of any power herein granted to the Holder,
but will suffer and permit the execution of every such as though no such law has been enacted.

(10) For purposes
of this Note, the following terms shall have the following meanings:

(a) “”
shall mean American Depositary Shares, each representing ten thousand (10,000) ordinary shares of the Company, nominal value £0.00005
per share.

(b) “”
means any day except Saturday, Sunday and any day which shall be a federal legal holiday in the United States or the United Kingdom or
a day on which banking institutions are authorized or required by law or other government action to close.

(c) “”
means the Securities and Exchange Commission.

(d) “”
means the Securities Exchange Act of 1934, as amended.

(e) “” means any material adverse effect on (i) the enforceability of this Note, (ii) the results of operations, assets, business
or financial condition of the Company and its Subsidiaries, taken as a whole, other than any material adverse effect that resulted primarily
from (A) any change in the United States or foreign economies or securities or financial markets in general that does not have a disproportionate
effect on the Company and its Subsidiaries, taken as a whole, (B) any change that generally affects the industry in which the Company
and its Subsidiaries operate that does not have a disproportionate effect on the Company and its Subs